NeuroVista
Founded Year
2004Stage
Debt | DeadTotal Raised
$62.6MLast Raised
$5MMissing: NeuroVista's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: NeuroVista's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
NeuroVista Patents
NeuroVista has filed 13 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/4/2012 | 3/12/2013 | Neurological disorders, Psychiatric diagnosis, Neurotechnology, Electroencephalography, Neurophysiology | Grant |
Application Date | 4/4/2012 |
|---|---|
Grant Date | 3/12/2013 |
Title | |
Related Topics | Neurological disorders, Psychiatric diagnosis, Neurotechnology, Electroencephalography, Neurophysiology |
Status | Grant |
Latest NeuroVista News
Dec 4, 2016
Printed From BioPortfolio.com NeuroVista Corporation formerly BioNeuronics Corporation Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 10:57 EST 4 Dec 2016 | BioPortfolio Reports Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » NeuroVista Corporation formerly BioNeuronics Corporation Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' NeuroVista Corporation formerly BioNeuronics Corporation Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by NeuroVista Corporation formerly BioNeuronics Corporation since January 2007. Key Findings Provides intelligence on NeuroVista Corporation formerly BioNeuronics Corporation MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by NeuroVista Corporation formerly BioNeuronics Corporation and its subsidiaries since 2007. Information about key financial and legal advisors for NeuroVista Corporation formerly BioNeuronics Corporation's financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about NeuroVista Corporation formerly BioNeuronics Corporation's growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News
NeuroVista Frequently Asked Questions (FAQ)
When was NeuroVista founded?
NeuroVista was founded in 2004.
Where is NeuroVista's headquarters?
NeuroVista's headquarters is located at 140 4th Avenue North, Seattle.
What is NeuroVista's latest funding round?
NeuroVista's latest funding round is Debt.
How much did NeuroVista raise?
NeuroVista raised a total of $62.6M.
Who are the investors of NeuroVista?
Investors of NeuroVista include Cyberonics, GBS Venture Partners, Flare Capital Partners, Three Arch Partners, Sprout Group and 6 more.
Who are NeuroVista's competitors?
Competitors of NeuroVista include MedShape, Autonomic Technologies, Cianna Medical, Inspire Medical Systems, TearScience and 12 more.
Compare NeuroVista to Competitors
Apneon is an early stage medical device company developing devices for the treatment of sleep apnea.
Beta-O2 Technologies is a biomedical company developing a proprietary implantable bioreactor, the ßAir. The company's flagship product is called the ßAir Bio-artificial Pancreas. It is in development as a treatment and potential cure for type 1 diabetes (T1D). ßAir was first designed to address the main problems of the otherwise successful procedures in which islets of Langerhans (i.e. pancreatic endocrine cells) are transplanted in diabetic patients, such as the need for life-long immunosuppressive pharmacological treatment and limited functionality of the transplanted islets over time due to an insufficient oxygen supply. The company's second pipeline product is the ßAir Bio-artificial Adrenal for the treatment of adrenocortical insufficiency and other stress-related disorders. This product is currently at the pre-clinical stage of development.
Linguaflex is a medical device company with a patent pending technology to treat obstructive sleep apnea. LinguaFlex's LTR is implanted and designed to be comfortable, therefore addressing the lack of compliance as an issue in the successful treatment of OSA.
Neuromonics is an Australian company that has developed an FDA approved device for treatment of tinnitus over a six month process with 2 hours of use per day.
Stealth mode medical device company developing devices for drug delivery. Monterey Devices submitted a patent on device for buffering anesthetics.
C2C is a medical device company developing a portfolio of medical devices.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.